A Prospective, Randomized, Phase II Study to Assess the Schemas of Retreatment with Lutathera® in Patients with New Progression of an Intestinal, Well-Differentiated Neuroendocrine Tumor (Reluth).
BMC cancer（2022）
关键词
177Lu-DOTA-TATE,PRRT,Neuroendocrine tumor,Overall survival,Progression-free survival,Quality of life
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要